TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact
背景

TST004

MASP2
Target:
MASP2
Indication:
TMA/IgA Nephropathy
Project Status:
Preclinical

TST004 is a humanized mAb targeting mannan-binding lectin serine protease 2 (MASP2) and designed to prevent the inflammation and tissue damage mediated by lectin pathway complement activation. TST004 is currently at IND-enabling stage with GLP toxicology studies and CMC studies ongoing.


t004.jpg

Nature Reviews Nephrology (2017) 13:311–318 


TOP